CliffBio
small molecule

ERZOFRI

PALIPERIDONE PALMITATE

Loss of exclusivitySeptember 2039latest FDA-listed patent expiry
CompanyLUYE INNOMIND PHARMA (SHIJIAZHUANG) CO LTD

Drug detail

Brand nameERZOFRI
Active ingredientPALIPERIDONE PALMITATE
Strength39MG/0.25ML (39MG/0.25ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

Listed patents

PatentExpiresType
11666573September 2039use U-3969
12128049October 2038use U-3969

More from LUYE INNOMIND PHARMA (SHIJIAZHUANG) CO LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ERZOFRI patent cliff — loss of exclusivity September 2039 | CliffBio